Scientists at St. Jude Children’s Research Hospital added a molecular anchor to chimeric antigen receptors (CARs), increasing the anti-cancer activity of cellular immunotherapies in cancer models.
Adding a molecular anchor to the key protein that recognizes cancer in cellular immunotherapies can make treatments significantly more effective. Scientists at St. Jude Children’s Research Hospital found that immune cells with the anchored protein increased cancer killing, regardless of the cancer’s cell type or the form of cancer targeted. The molecular anchor concept is a new design for improving chimeric antigen receptor (CAR)-based-immunotherapies. CARs have shown some promise in the clinic but have yet to deliver widespread success across tumor types. The findings were published in Nature Biotechnology.